MYGN, FIRE, FURX, - CRWESelect.com Stock News! Myriad Genetics, Sourcefire, Furiex Pharmaceuticals (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) November 1, 2011 -- To view video, and read the full article visit URL http://crweselect.com/27130/stock-alerts/mygn-fire-furx-crweselectcom-stock-news-myriad-genetics-sourcefire-furiex-pharmaceuticals-video-included-inside/

Myriad Genetics, Inc. (NASDAQ:MYGN)

MYGN announced today results for its first fiscal quarter ending September 30, 2011. Revenue for the first fiscal quarter was $110.5 million, an increase of 20 percent over the $91.9 million reported in the first fiscal quarter of 2011. Operating income was $41.5 million, an increase of 17 percent from the prior-year period.

MYGN is a leading molecular diagnostic company dedicated to developing and marketing transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess a patient's risk of disease progression and disease recurrence. MYGN portfolio of nine molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a focus on improving an individual's decision making process for monitoring and treating disease. With fiscal year 2011 annual revenue of over $400 million and more than 1,000 employees, MYGN is working on strategic directives, including new product introductions, companion diagnostics, and international expansion, to take advantage of significant growth opportunities.

For more information about MYGN please visit http://www.myriad.com/

****

Sourcefire, Inc. (NASDAQ:FIRE)

FIRE announced today financial results for its fiscal third quarter ended September 30, 2011. Revenue for the third quarter of 2011 was $45.2 million compared to $36.2 million in the third quarter of 2010, an increase of 25%. Adjusted net income for the third quarter of 2011, which excludes stock-based compensation expense, amortization of acquired intangible assets and other acquisition-related expenses, and includes an assumed tax rate of 35%, was $5.7 million, or $0.19 per diluted share. This compares to adjusted net income of $5.2 million, or $0.18 per diluted share, in the third quarter of 2010, which excludes stock-based compensation expense and assumes a tax rate of 35%.

FIRE, a world leader in intelligent cybersecurity solutions, is transforming the way Global 2000 organizations and government agencies manage and minimize network security risks. With solutions from the network to the endpoint, FIRE provides customers with Agile SecurityTM that is as dynamic as the real world it protects and the attackers against which it defends. Trusted for more than 10 years, FIRE has been consistently recognized for its innovation and industry leadership with dozens of patents, world-class research, and award-winning technology. Today, the name Sourcefire has grown synonymous with innovation, security intelligence and agile end-to-end security infrastructure.

For more information about FIRE please visit http://www.sourcefire.com/

****

Furiex Pharmaceuticals, Inc. (NASDAQ:FURX)

FURX announced today that it has acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. FURX acquired these rights as a result of Janssen’s decision, after an evaluation of strategic fit within its late stage portfolio, not to exercise its option under the agreement to continue development of MuDelta. FURX will owe payments to Janssen based on Phase III trial initiation, future regulatory milestones and, if the product is approved, sales milestones and royalties.

Also, FURX reported today its financial and operating results for the quarter ended September 30, 2011. FURX recorded third quarter royalty revenues of $1.3 million, compared to $0.3 million for the same period in the prior year. Royalty revenue included royalties related to Priligy™ sales in various countries outside of the United States and Nesina® sales in Japan.

FURX is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of partnered drug programs by advancing them through the drug discovery and development process in a cost-efficient manner. Development programs are designed and driven by a core team with extensive drug development experience. The company collaborates with pharmaceutical and biotechnology companies and has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates including late-stage assets and two products on the market. The company’s mission is to develop innovative medicines faster and at less cost, reducing the expense of health care globally while providing life-improving therapies for patients.

For more information about FURX please visit http://www.furiex.com/

To read the full article visit URL http://crweselect.com/27130/stock-alerts/mygn-fire-furx-crweselectcom-stock-news-myriad-genetics-sourcefire-furiex-pharmaceuticals-video-included-inside/

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

MYGNcrweselect1101
FIREcrweselect1101
FURXcrweselect1101

fire     Furiex Pharmaceuticals     FURX     Janssen Pharmaceutica     MYGN     Myriad Genetics     NASDAQ MYGN     sourcefire